Maknotte

Zopiclone, the active ingredient in Maknotte, is a cyclopyrrolone (non‑benzodiazepine hypnotic) presented as an oral tablet for oral administration. Classified under ATC code N05CF01, it belongs to the sedative/hypnotic therapeutic class and is used to treat insomnia by facilitating sleep onset and maintenance in adult patients.

GNH USA supplies Maknotte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring the product meets European pharmacopeial standards and is available for bulk and unit‑dose distribution.

Zopiclone is indicated for insomnia, a sleep disorder characterized by difficulty initiating or maintaining sleep. - Insomnia (difficulty falling asleep): helps patients initiate sleep more quickly. - Insomnia (difficulty maintaining sleep): reduces nocturnal awakenings and prolongs sleep duration. - Generalized insomnia: improves overall sleep quality and next‑day functioning.

Zopiclone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Bitter or metallic taste: transient alteration in oral sensation. - Drowsiness or fatigue: feeling sleepy during daytime. - Dry mouth: reduced salivary flow. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Complex sleep behaviours: sleepwalking, sleep‑driving, or performing other activities while not fully awake. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Mood changes: depression, anxiety, or suicidal thoughts. - Respiratory depression: slowed breathing, especially when combined with other depressants. - Memory impairment: amnesia for events occurring after dosing.

Before prescribing Zopiclone, clinicians should consider several safety precautions to minimize risks. - Avoid alcohol: concurrent use can intensify sedation and respiratory depression. - Use caution in elderly: increased sensitivity may lead to falls and cognitive impairment. - Do not operate machinery: impaired alertness can affect driving or use of hazardous equipment. - Pregnancy category B: limited data suggest relative safety, but use only if clearly needed. - Renal or hepatic impairment: dose adjustment may be required due to altered metabolism. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Zopiclone can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations and heighten sedation. - Opioids (e.g., morphine, oxycodone): additive central nervous system depression can be dangerous. - Other hypnotics or sedatives (e.g., benzodiazepines, barbiturates): risk of profound sedation and respiratory compromise.

Moderate Interactions (Monitor Closely): - Alcohol and CNS depressants: enhance drowsiness and impair coordination. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Antidepressants (e.g., fluoxetine, sertraline): can increase sedation or affect metabolism.